Rigel Pharmaceuticals
RIGL
133 hedge funds and large institutions have $365M invested in Rigel Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 50 increasing their positions, 32 reducing their positions, and 16 closing their positions.
96% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $881K
56% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 32
0.11% more ownership
Funds ownership: 9.41% → 9.52% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 135 → 133 (-2)
27% less capital invested
Capital invested by funds: $503M → $365M (-$138M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.69M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.91M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.29M |
| 4 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$2.68M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.86M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$7.45M |
| 3 |
Millennium Management
New York
|
-$2.13M |
| 4 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$1.52M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.17M |
RIGL Hedge Fund Activity: Q4 2018 in Review
133 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2018, worth a combined $365M — down 27% from $503M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RIGL and 15 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 50 added.
The largest buyer was Goldman Sachs, adding an estimated $5.69M. The largest seller was Vanguard Group, cutting an estimated $7.86M.
- 133 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2018, down from 135 in Q3 2018.
- Funds reported $365M of Rigel Pharmaceuticals stock for Q4 2018, down 27% quarter-over-quarter.
- 15 funds opened new Rigel Pharmaceuticals positions in Q4 2018 and 16 closed out, a net change of -1 holder.
- The largest Rigel Pharmaceuticals buyer in Q4 2018 was Goldman Sachs, an estimated $5.69M added.
- The largest Rigel Pharmaceuticals seller in Q4 2018 was Vanguard Group, an estimated $7.86M sold.
Based on aggregated 13F filings for Q4 2018.